TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 21377689

Group type: EXPERIMENTAL
Intervention: Presence of a watchful invisible person ('Princess Alice')
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Observation by a real adult
Number of subjects: 0

Group type: COMPARATOR
Intervention: Unsupervised condition
Number of subjects: 0
Study: 19139780

Group type: EXPERIMENTAL
Intervention: High dose folic acid (5 mg/day)
Number of subjects: 246

Group type: COMPARATOR
Intervention: Low dose folic acid (0.5 mg/day)
Number of subjects: 246
Study: 17716344

Group type: EXPERIMENTAL
Intervention: Osteopathy (OG)
Number of subjects: 39

Group type: COMPARATOR
Intervention: Standard Care (SCG)
Number of subjects: 39
Study: 15215111

Group type: EXPERIMENTAL
Intervention: BAL5788 at 500 mg
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: BAL5788 at 750 mg
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study: 15607398

Group type: EXPERIMENTAL
Intervention: RSD-2 (2 mg/kg followed by 3 mg/kg)
Number of subjects: 56
Study: 11303205

Group type: EXPERIMENTAL
Intervention: Isosorbide mononitrate 20 mg
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Isosorbide mononitrate 40 mg
Number of subjects: 34

Group type: COMPARATOR
Intervention: Vaginal examination only
Number of subjects: 34
Study: 9278949

Group type: EXPERIMENTAL
Intervention: Apomorphine (APO; 0.75 mg sc)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Normal controls
Number of subjects: 24
Study: 8354726

Group type: EXPERIMENTAL
Intervention: Topically-applied light-cured resin
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo, sham light-cured
Number of subjects: 10
Study: 3016226

Group type: EXPERIMENTAL
Intervention: Oral metoclopramide (0.5 mg/kg/24 h)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Liquid alginic acid‐antacid compound
Number of subjects: 0
Study: 27783535

Group type: EXPERIMENTAL
Intervention: Positive prime (portraying older individuals as an asset)
Number of subjects: 51

Group type: COMPARATOR
Intervention: Negative prime (portraying older individuals as a burden)
Number of subjects: 51
Study: 27673363

Group type: EXPERIMENTAL
Intervention: Serum metabolomic profiling
Number of subjects: 380
Study: 24732940

Group type: EXPERIMENTAL
Intervention: Artemether-lumefantrine (AL)
Number of subjects: 160

Group type: EXPERIMENTAL
Intervention: Artesunate-amodiaquine (ASAQ)
Number of subjects: 160

Group type: EXPERIMENTAL
Intervention: Artesunate-amodiaquine-chlorpheniramine (AQC)
Number of subjects: 160
Study: 23773981

Group type: EXPERIMENTAL
Intervention: 8 h of uninterrupted sitting (Sedentary)
Number of subjects: 19

Group type: COMPARATOR
Intervention: 8 h of sitting interrupted with a 2‐min light‐intensity walk break every 20 min (Breaks)
Number of subjects: 19

Group type: COMPARATOR
Intervention: 8 h of sitting interrupted with a 2‐min light‐intensity walk break every 20 min and 2×20 min of moderate‐intensity physical activity (Breaks+Physical Activity)
Number of subjects: 19
Study: 20221357

Group type: EXPERIMENTAL
Intervention: Student response system used during lecture
Number of subjects: 179

Group type: COMPARATOR
Intervention: No student response system used during lecture (Control)
Number of subjects: 179
Study: 18590223

Group type: EXPERIMENTAL
Intervention: Postoperative satisfaction rate in patients with BDD
Number of subjects: 0

Group type: COMPARATOR
Intervention: Postoperative satisfaction rate in patients without BDD
Number of subjects: 0
Study: 16637759

Group type: EXPERIMENTAL
Intervention: Envy as a predictor of Schadenfreude when the target is similar in gender to the observer.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 0
Study: 12641480

Group type: EXPERIMENTAL
Intervention: Active treatment with an ACE inhibitor-based blood pressure-lowering regimen (perindopril) with or without indapamide
Number of subjects: 6105

Group type: COMPARATOR
Intervention: Matched placebo
Number of subjects: 6105
Study: 10563643

Group type: EXPERIMENTAL
Intervention: Aspirin
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Acetaminophen
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Acetaminophen with codeine
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 8752793

Group type: EXPERIMENTAL
Intervention: Dipyridamole stress echocardiography
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Dobutamine stress echocardiography
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Dipyridamole or Dobutamine stress echocardiography
Number of subjects: 70
Study: 1998307

Group type: EXPERIMENTAL
Intervention: Diltiazem (60-90 mg qid)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 22
Study: 6660459

Group type: EXPERIMENTAL
Intervention: 50 mg metoprolol
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: 100 mg metoprolol
Number of subjects: 90

Group type: COMPARATOR
Intervention: No metoprolol
Number of subjects: 90
Study: 31299810

Group type: EXPERIMENTAL
Intervention: Postintubation TS patients
Number of subjects: 55
Study: 28368936

Group type: EXPERIMENTAL
Intervention: Computer-controlled intermittent boluses of phenylephrine
Number of subjects: 214

Group type: COMPARATOR
Intervention: Computer-controlled continuous infusion of phenylephrine
Number of subjects: 214
Study: 26245910

Group type: EXPERIMENTAL
Intervention: Community mobilization intervention (CM)
Number of subjects: 1200

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 1200
Study: 24187114

Group type: EXPERIMENTAL
Intervention: Home Visiting (HV)
Number of subjects: 707

Group type: COMPARATOR
Intervention: Control group (referred to other service providers)
Number of subjects: 707
Study: 21896097

Group type: EXPERIMENTAL
Intervention: Rifaximin 550 mg once daily for 14 days
Number of subjects: 101

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 101
Study: 18657102

Group type: EXPERIMENTAL
Intervention: Attribute framing in discrete choice experiments (DCE)
Number of subjects: 1920

Group type: EXPERIMENTAL
Intervention: Accuracy of the test for finding cancer
Number of subjects: 1920

Group type: EXPERIMENTAL
Intervention: Accuracy of the test for finding large polyps
Number of subjects: 1920

Group type: EXPERIMENTAL
Intervention: Framing of attributes (e.g., cancers found vs. cancers missed)
Number of subjects: 1920
Study: 17366759

Group type: COMPARATOR
Intervention: Conventional toothbrush with horizontal scrubbing (conventional group)
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: Conventional toothbrush with transverse technique (modified group)
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: End‐tufted toothbrush (end‐tufted group)
Number of subjects: 37
Study: 15034230

Group type: EXPERIMENTAL
Intervention: Zolpidem (10 mg)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Zaleplon (10 mg)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 11981593

Group type: EXPERIMENTAL
Intervention: Triazolam (0.125 or 0.25 mg)
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Triazolam
Number of subjects: 44

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 44
Study: 9534649

Group type: EXPERIMENTAL
Intervention: Gas jet method
Number of subjects: 0
Study: 8550169

Group type: EXPERIMENTAL
Intervention: Dynamic hip screw (DHS)
Number of subjects: 95

Group type: COMPARATOR
Intervention: Gamma nail
Number of subjects: 95
Study: 2197836

Group type: EXPERIMENTAL
Intervention: Drained group (26 patients)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Undrained group (24 patients)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Drained group
Number of subjects: 50

Group type: COMPARATOR
Intervention: Undrained group
Number of subjects: 50
Study: 363479

Group type: EXPERIMENTAL
Intervention: mianserin 10 mg
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: mianserin 20 mg
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: amitriptyline 25 mg
Number of subjects: 8

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 8
Study: 7045017

Group type: EXPERIMENTAL
Intervention: viloxazine
Number of subjects: 123

Group type: COMPARATOR
Intervention: imipramine
Number of subjects: 123

Group type: COMPARATOR
Intervention: amitriptyline
Number of subjects: 123

Group type: COMPARATOR
Intervention: doxepin
Number of subjects: 123

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 123
Study: 31182062

Group type: EXPERIMENTAL
Intervention: Tablet-based intervention including a screening questionnaire for violence and a video on violence and safety behaviours.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group receiving a video with general information about a healthy and safe pregnancy.
Number of subjects: 0
Study: 29926087

Group type: EXPERIMENTAL
Intervention: Dialectical Behavior Therapy (DBT)
Number of subjects: 173

Group type: COMPARATOR
Intervention: Individual and Group Supportive Therapy (IGST)
Number of subjects: 173
Study: 26528704

Group type: EXPERIMENTAL
Intervention: Reverse trendelenburg position (group 1)
Number of subjects: 146

Group type: COMPARATOR
Intervention: Routine surgical procedure (group 2)
Number of subjects: 146
Study: 25222672

Group type: EXPERIMENTAL
Intervention: GAL021 (high-dose)
Number of subjects: 20

Group type: COMPARATOR
Intervention: GAL021
Number of subjects: 20
Study: 22790614

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 435

Group type: COMPARATOR
Intervention: Mailed refill reminders
Number of subjects: 435

Group type: COMPARATOR
Intervention: Illustrated medication schedules
Number of subjects: 435

Group type: COMPARATOR
Intervention: Both interventions
Number of subjects: 435

Group type: EXPERIMENTAL
Intervention: Illustrated medication schedules (post-hoc analysis)
Number of subjects: 435
Study: 21162725

Group type: EXPERIMENTAL
Intervention: RBC transfusion
Number of subjects: 500

Group type: COMPARATOR
Intervention: Expectant management
Number of subjects: 500
Study: 17901854

Group type: EXPERIMENTAL
Intervention: Paravertebral block
Number of subjects: 60

Group type: COMPARATOR
Intervention: General anesthesia
Number of subjects: 60
Study: 15327617

Group type: EXPERIMENTAL
Intervention: Sublingual misoprostol 400 microg every 3 hours for a maximum of five doses
Number of subjects: 224

Group type: COMPARATOR
Intervention: Vaginal misoprostol 400 microg every 3 hours for a maximum of five doses
Number of subjects: 224
Study: 11509481

Group type: EXPERIMENTAL
Intervention: Caffeinated coffee (150 mg caffeine)
Number of subjects: 7

Group type: COMPARATOR
Intervention: Decaffeinated coffee (<2 mg caffeine)
Number of subjects: 7
Study: 9315535

Group type: EXPERIMENTAL
Intervention: Octreotide
Number of subjects: 217

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 217
Study: 8335138

Group type: EXPERIMENTAL
Intervention: Retropubic urethrocystopexy (n = 22)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Pubococcygeal repair (n = 14)
Number of subjects: 36
Study: 3523395

Group type: EXPERIMENTAL
Intervention: GSR feedback
Number of subjects: 31

Group type: COMPARATOR
Intervention: Schultz relaxation
Number of subjects: 31
Study: 29105023

Group type: EXPERIMENTAL
Intervention: Bonded RME
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Banded RME
Number of subjects: 30

Group type: COMPARATOR
Intervention: Untreated control group
Number of subjects: 30
Study: 26108136

Group type: EXPERIMENTAL
Intervention: PGS with FES
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: PGS with TES
Number of subjects: 5

Group type: COMPARATOR
Intervention: PGS alone
Number of subjects: 5

Group type: COMPARATOR
Intervention: Strong CPN stimulation (FES) alone
Number of subjects: 5

Group type: COMPARATOR
Intervention: Weak CPN stimulation (TES) alone
Number of subjects: 5
Study: 24572077

Group type: EXPERIMENTAL
Intervention: 4 Gy in two fractions
Number of subjects: 615

Group type: COMPARATOR
Intervention: 24 Gy in 12 fractions
Number of subjects: 615
Study: 21606949

Group type: EXPERIMENTAL
Intervention: Warfarin dosing strategies (pharmacogenetic dosing)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Lower target international normalized ratio (INR)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Composite primary endpoint
Number of subjects: 0
Study: 19651954

Group type: EXPERIMENTAL
Intervention: ChloraPrep (2% chlorhexidine gluconate and 70% isopropyl alcohol)
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: DuraPrep (0.7% iodophor and 74% isopropyl alcohol)
Number of subjects: 150

Group type: COMPARATOR
Intervention: povidone-iodine scrub and paint (0.75% iodine scrub and 1.0% iodine paint)
Number of subjects: 150
Study: 17456569

Group type: EXPERIMENTAL
Intervention: Growth Hormone (GH) 0.67 mg/d
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study: 14735126

Group type: EXPERIMENTAL
Intervention: Trihexyphenidyl (1 mg)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Trihexyphenidyl (2 mg)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study: 11472048

Group type: EXPERIMENTAL
Intervention: Arm vein grafts
Number of subjects: 200

Group type: COMPARATOR
Intervention: Greater saphenous vein grafts
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Arm vein grafts (cephalic vein)
Number of subjects: 200
Study: 9973776

Group type: EXPERIMENTAL
Intervention: Kung fu forms protocol (30 sec work, 30 sec rest)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Kung fu punching protocol (30 sec work, 30 sec rest)
Number of subjects: 18
Study: 7821746

Group type: EXPERIMENTAL
Intervention: C-peptide administration
Number of subjects: 0
Study: 3062253

Group type: EXPERIMENTAL
Intervention: Rapid rotation (change of drugs every 2-3 weeks)
Number of subjects: 109

Group type: COMPARATOR
Intervention: Slow rotation (change of drugs every 4-6 weeks)
Number of subjects: 109

Group type: EXPERIMENTAL
Intervention: Both groups (Rapid and Slow rotation)
Number of subjects: 109

Group type: EXPERIMENTAL
Intervention: Rapid rotation arm
Number of subjects: 109

Group type: EXPERIMENTAL
Intervention: Patients with initial white blood count >= 100/nl
Number of subjects: 109
Study: 30758417

Group type: EXPERIMENTAL
Intervention: saxagliptin
Number of subjects: 95

Group type: COMPARATOR
Intervention: glimepiride
Number of subjects: 95

Group type: COMPARATOR
Intervention: glimepiride combined with polyene phosphatidylcholine
Number of subjects: 95
Study: 28583162

Group type: EXPERIMENTAL
Intervention: Methylprednisolone (1 mg/kg daily for 3 weeks)
Number of subjects: 202

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 202
Study: 26496361

Group type: EXPERIMENTAL
Intervention: Oral glucose (25%)
Number of subjects: 104

Group type: EXPERIMENTAL
Intervention: Facilitated tucking with oral glucose
Number of subjects: 104

Group type: COMPARATOR
Intervention: Oral water (placebo)
Number of subjects: 104

Group type: EXPERIMENTAL
Intervention: Facilitated tucking with oral water
Number of subjects: 104
Study: 23369426

Group type: EXPERIMENTAL
Intervention: Both written and oral information modalities
Number of subjects: 140

Group type: COMPARATOR
Intervention: Written information modality (information sheet)
Number of subjects: 140

Group type: COMPARATOR
Intervention: Oral information modality (presentation)
Number of subjects: 140
Study: 21411805

Group type: EXPERIMENTAL
Intervention: Clinical decision support (CDS) integrated into a computerized prescriber-order-entry (CPOE) system
Number of subjects: 216

Group type: COMPARATOR
Intervention: Control group with aminoglycoside orders monitored by pharmacists
Number of subjects: 216
Study: 19543566

Group type: EXPERIMENTAL
Intervention: Standard treatment
Number of subjects: 4361

Group type: EXPERIMENTAL
Intervention: Randomized treatment of acute bipolar depression
Number of subjects: 4361

Group type: EXPERIMENTAL
Intervention: Bipolar depression and refractory relapse prevention
Number of subjects: 4361
Study: 17605959

Group type: EXPERIMENTAL
Intervention: High-intensity interval walking training
Number of subjects: 246

Group type: COMPARATOR
Intervention: Moderate-intensity continuous walking training
Number of subjects: 246
Study: 15292331

Group type: EXPERIMENTAL
Intervention: Metformin (1000 mg twice a day)
Number of subjects: 55

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 55
Study: 11199350

Group type: EXPERIMENTAL
Intervention: Recombinant human erythropoietin (12,000 U per week)
Number of subjects: 73
Study: 9657323

Group type: EXPERIMENTAL
Intervention: Mycobacterium vaccae immunotherapy
Number of subjects: 35

Group type: COMPARATOR
Intervention: Placebo (tetanus toxoid)
Number of subjects: 35
Study: 8130050

Group type: EXPERIMENTAL
Intervention: flunitrazepam-fentanyl 0.01 mg kg-1 for induction and maintained with flunitrazepam-fentanyl 1.2 mg h-1
Number of subjects: 60

Group type: COMPARATOR
Intervention: etomidate 0.25 mg kg-1 and fentanyl 0.005 mg kg-1 for induction and 0.6-1.2 vol% isoflurane and fentanyl 1.2 mg h-1 for maintenance
Number of subjects: 60

Group type: COMPARATOR
Intervention: propofol 4-8 mg kg-1 h-1 and fentanyl 1.2 mg h-1 for maintenance
Number of subjects: 60
Study: 2775883

Group type: EXPERIMENTAL
Intervention: Tetracosactide (D1: 3 mg, D2 and D3: 2 mg/d)
Number of subjects: 102

Group type: EXPERIMENTAL
Intervention: Methylprednisolone (D1: 240 mg, D2 and D3: 160 mg/d)
Number of subjects: 102

Group type: EXPERIMENTAL
Intervention: Tetracosactide (7 mg for 3 days)
Number of subjects: 102
Study: 30427093

Group type: EXPERIMENTAL
Intervention: Oral nanocurcumin (120 mg/day)
Number of subjects: 64

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 64
Study: 28483557

Group type: EXPERIMENTAL
Intervention: Minimalist shoes
Number of subjects: 61

Group type: COMPARATOR
Intervention: Conventional shoes
Number of subjects: 61
Study: 26076828

Group type: EXPERIMENTAL
Intervention: PDL-0101 (1.8 g/d eicosapentaenoic acid; 12 mg/d astaxanthin; 100 mg/d tocopherol-free gamma/delta tocotrienols enriched with geranylgeraniol)
Number of subjects: 102

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 102

Group type: EXPERIMENTAL
Intervention: PDL-0101
Number of subjects: 102
Study: 23874465

Group type: EXPERIMENTAL
Intervention: Probiotic supplementation
Number of subjects: 454

Group type: COMPARATOR
Intervention: Control group (placebo)
Number of subjects: 454

Group type: EXPERIMENTAL
Intervention: Retention rates at 6 months and 2 years
Number of subjects: 454

Group type: EXPERIMENTAL
Intervention: Consent to infant blood sample donation
Number of subjects: 454

Group type: EXPERIMENTAL
Intervention: Interest in probiotics or research
Number of subjects: 454
Study: 21751888

Group type: EXPERIMENTAL
Intervention: Intensive treatment group with self-monitoring of blood glucose (SMBG) profiles (six or seven values per day, 3 days/week) and weekly clinic visits
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: Intensive treatment group
Number of subjects: 63

Group type: COMPARATOR
Intervention: Control group with glucose profiles and clinic visits at Weeks 0, 6, and 12
Number of subjects: 63

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 63
Study: 19329498

Group type: EXPERIMENTAL
Intervention: NGAL levels in patients with acute post-MI HF
Number of subjects: 386

Group type: EXPERIMENTAL
Intervention: Baseline NGAL levels in patients with HF following acute MI
Number of subjects: 386

Group type: EXPERIMENTAL
Intervention: NGAL/lipocalin-2 gene expression in a rat model of post-MI HF
Number of subjects: 386

Group type: EXPERIMENTAL
Intervention: NGAL immunostaining in cardiomyocytes
Number of subjects: 386

Group type: EXPERIMENTAL
Intervention: Interleukin-1beta and agonists for toll-like receptors 2 and 4
Number of subjects: 386
Study: 16704555

Group type: EXPERIMENTAL
Intervention: Glipizide 2.5 mg once daily for 6 months
Number of subjects: 37

Group type: COMPARATOR
Intervention: Placebo for 6 months
Number of subjects: 37
Study: 15600124

Group type: EXPERIMENTAL
Intervention: Navigation system (group 2)
Number of subjects: 50

Group type: COMPARATOR
Intervention: No navigation system (group 1)
Number of subjects: 50
Study: 11711900

Group type: EXPERIMENTAL
Intervention: Adenosine
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Arbutamine
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Dobutamine
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Comparison of adenosine and arbutamine
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Comparison of dobutamine and adenosine
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Comparison of arbutamine and dobutamine
Number of subjects: 40
Study: 9563983

Group type: EXPERIMENTAL
Intervention: Integrated social and medical care and case management
Number of subjects: 200

Group type: COMPARATOR
Intervention: Control group (conventional care)
Number of subjects: 200
Study: 1857516

Group type: EXPERIMENTAL
Intervention: Intravaginal 1 mg Gemeprost
Number of subjects: 89

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 89
Study: 6846762

Group type: EXPERIMENTAL
Intervention: Left lateral position
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Right lateral position
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Left 15 degrees tilt position
Number of subjects: 30

Group type: COMPARATOR
Intervention: Right 15 degrees tilt position
Number of subjects: 30
Study: 30793431

Group type: COMPARATOR
Intervention: Elobixibat 10 mg/d
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Elobixibat 15 mg/d
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Elobixibat (varied doses 5-15 mg/d)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 28270028

Group type: EXPERIMENTAL
Intervention: Health Education Session (HES) administered to the Intervention Group (IG)
Number of subjects: 92
Study: 28404657

Group type: COMPARATOR
Intervention: Routine Care (RC)
Number of subjects: 371

Group type: EXPERIMENTAL
Intervention: DiabetesDriving.com (DD.com)
Number of subjects: 371
Study: 23968203

Group type: EXPERIMENTAL
Intervention: VSL#3(®)
Number of subjects: 17

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 17
Study: 21846617

Group type: EXPERIMENTAL
Intervention: Insulin glargine once daily in addition to standard treatment
Number of subjects: 36

Group type: COMPARATOR
Intervention: Standard treatment (control group)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 36
Study: 19205663

Group type: EXPERIMENTAL
Intervention: 40 mg of simvastatin orally, followed by 20 mg of simvastatin
Number of subjects: 83

Group type: COMPARATOR
Intervention: Matching placebo
Number of subjects: 83
Study: 17288331

Group type: EXPERIMENTAL
Intervention: iBond
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: G‐Bond
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Xeno IV
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Clearfil S3 Bond
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control (no adhesive)
Number of subjects: 60
Study: 15109523

Group type: EXPERIMENTAL
Intervention: Motor imagery program (MIP)
Number of subjects: 13

Group type: COMPARATOR
Intervention: Control group (ongoing management)
Number of subjects: 13